01—Abstract
Summary
Summary of the 10-K filed February 12, 2025. Cited figures are marked; the original filing is the authoritative source.
Biogen's FY2024 Form 10-K (filed February 12, 2025) shows a company in transition: total revenue fell 1.6% to $9.68 billiona, while diluted EPS rose 40.3% to $11.18, helped by lower R&D and SG&A spending under the Fit for Growth cost program and by a $1.6 billion increase in amortization and impairment charges that was more than offset elsewhere.
Product revenue was essentially flat at $7.21 billionb, with MS revenue down 6.7% to $4.35 billion because of TECFIDERA generic erosion, TYSABRI competition and lower interferon demand. Rare disease grew 10.3% to $1.99 billion, led by the first full year of SKYCLARYS ($382.5 million) and ZURZUVAE, though this was partly offset by lower SPINRAZA sales outside the U.S. The balance sheet and cash flow improved. Operating cash flow rose 86% to $2.88 billion, cash and equivalents reached $2.38 billion, and the company repaid $650 million of its 2023 term loan.
Total borrowings fell to $6.30 billionc, but $1.75 billion of 4.05% Senior Notes mature in September 2025, which pushed current liabilities up sharply and reduced working capital to $1.93 billion. The company completed the $1.15 billion HI-Bio acquisition, which added the felzartamab pipeline and roughly $650 million of potential milestones, and sold its rare pediatric priority review voucher for $88.6 million net. No share repurchases were made in 2024, leaving about $2.1 billion authorized.
The main investor concerns are the continued decline of the MS franchise, biosimilar and generic pressure on RITUXAN, TECFIDERA and TYSABRI, IRA-related revenue headwinds estimated at $50d-100 million for 2025, and the LEQEMBI launch, which still depends on EU and Australia regulatory outcomes. Management expects MS revenue to keep declining in 2025 while rare disease grows. Core R&D is expected to fall, but the company is still funding pipeline investments and facing a 2025 debt maturity wall.
02—Key points
Key Highlights
- Total revenue fell 1.6% to $9,675.9 million, while diluted EPS increased 40.3% to $11.18, driven by lower operating expenses (total cost and expense down 9.0%).
- Multiple Sclerosis product revenue declined 6.7% to $4,349.8 million, mainly due to TECFIDERA generics, TYSABRI biosimilar and rest-of-world pricing pressure; management expects continued MS decline in 2025.
- Rare disease revenue rose 10.3% to $1,988.1 million, with global SKYCLARYS revenue of $382.5 million, ZURZUVAE $72.2 million and QALSODY $32.4 million, partly offset by lower rest-of-world SPINRAZA sales.
- Operating cash flow increased 85.9% to $2,875.5 million; year-end cash and equivalents were $2,375.0 million, and $650.0 million of 2023 term loan debt was repaid.
- Working capital fell to $1,928.0 million from $3,425.0 million because $1.75 billion of 4.05% Senior Notes due September 2025 were reclassified to current liabilities.
- Acquired Human Immunology Biosciences (HI-Bio) for $1.15 billion in July 2024, adding felzartamab; up to $650 million in additional milestones may be payable, with about $300 million expected in 2025.
- Expects IRA Medicare Part D redesign to reduce 2025 revenue by roughly $50-100 million; no share repurchases were made in 2024, with about $2.1 billion remaining under the 2020 program.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2024filed February 12, 2025Financial Statements
FY2024 against FY2023
| Line item | FY2024FY2023 | Change |
|---|---|---|
| Revenue | $9.68B$9.84B | −1.6% |
| Cost of Revenue | $2.31B$2.53B | −8.8% |
| Gross Profit | $7.37B$7.30B | +0.9% |
| SG&A Expenses | $2.40B$2.55B | −5.7% |
| Operating Expenses | $7.77B$8.54B | −9.0% |
| Interest Expense | $250.30M$246.90M | +1.4% |
| Net Income | $1.63B$1.16B | +40.6% |
| EPS (Basic) | $11.21$8.02 | +39.8% |
| EPS (Diluted) | $11.18$7.97 | +40.3% |
| Shares Outstanding (Basic) | 145.60M144.70M | +0.6% |
| Shares Outstanding (Diluted) | 145.90M145.60M | +0.2% |
05—Questions
Frequently Asked Questions
How did Biogen's profitability improve in 2024 despite lower revenue?
Net income attributable to Biogen rose to $1,632.2 million from $1,161.1 million, mainly because total costs fell $768.9 million (9.0%). Research and development expense dropped $420.2 million, largely because 2023 included about $197 million of Reata-related equity compensation, and SG&A fell $146.0 million. Cost of sales decreased $223.0 million. Amortization and impairment of intangibles increased $206.1 million, partly offsetting these gains.
What is the biggest risk to Biogen's revenue outlook?
The MS franchise is the largest risk. TECFIDERA faces multiple generic entrants in North America, Brazil and parts of Europe, and TYSABRI faces biosimilar competition. Management expects total MS revenue to keep declining in 2025. Biosimilar competition to RITUXAN is also expected to reduce Biogen's share of U.S. co-promotion profits. Biogen is also defending the EP 2 653 873 TECFIDERA patent in European opposition and litigation with mixed results.
What are Biogen's near-term debt and liquidity considerations?
Total borrowings were $6.30 billion at year-end 2024, including $1.75 billion of 4.05% Senior Notes due September 15, 2025. Cash and equivalents of $2.38 billion, operating cash flow of $2.88 billion, and an undrawn $1.5 billion revolving credit facility maturing in 2029 provide coverage. The company also expects to pay HI-Bio milestones of about $150 million each in 2025 and a $234 million Transition Toll Tax installment within one year. Management states existing funds and cash flow are sufficient for the foreseeable future.
What are the key pipeline and commercial catalysts for 2025?
Key catalysts include an FDA decision on the LEQEMBI subcutaneous autoinjector with a PDUFA date of August 31, 2025, and an EMA review of LEQEMBI in the EU following safety discussions at the February 2025 CHMP meeting. Also pending are FDA and EMA reviews of a higher-dose SPINRAZA regimen, felzartamab development in IgAN, AMR and PMN, and a second Phase 3 study of dapirolizumab pegol in SLE started in late 2024. Biogen also expects SKYCLARYS revenue growth in 2025 as it launches in the U.S. and Europe.
Did Biogen change its capital return policy or leadership?
Biogen made no share repurchases in 2024 or 2023 and has not paid dividends since inception, though management says it continually reviews capital allocation. On management, Michael McDonnell, CFO, is retiring March 1, 2025, and Robin Kramer, the current Chief Accounting Officer, will become CFO. Sean Godbout will become Chief Accounting Officer and Global Corporate Controller.
06—Continue